Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julianne Peabody

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperatureJulianne Peabody, Pavan Muttil, Bryce Chackerian, et al.
Vaccine|August 13, 2013
A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvantsEbenezer Tumban, Julianne Peabody, David S Peabody, et al.
Plos One|August 23, 2011
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2Ebenezer Tumban, Julianne Peabody, David S Peabody, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
RNA Phage VLP-Based Vaccine PlatformsDavid S Peabody, Julianne Peabody, Steven B Bradfute, et al.
Biorxiv : the Preprint Server for Biology|April 22, 2024
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathyJonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
Research Square|July 1, 2024
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathyJonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
Plos One|October 31, 2015
Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle PlatformJerri Caldeira, Jeremiah Bustos, Julianne Peabody, et al.
Journal of Molecular Biology|April 20, 2011
Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particlesBryce Chackerian, Jerri do Carmo Caldeira, Julianne Peabody, et al.
Plos One|November 28, 2012
VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusEbenezer Tumban, Julianne Peabody, Mitchell Tyler, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
A VLP-based immunogen that elicits selective anti-Myostatin antibodies, enhances muscle mass and strength, and reduces adiposityQuiteria Jacquez, Julianne Peabody, Eduardo Hernandez Acosta, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperatureJulianne Peabody, Pavan Muttil, Bryce Chackerian, et al.
Vaccine|August 13, 2013
A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvantsEbenezer Tumban, Julianne Peabody, David S Peabody, et al.
Plos One|August 23, 2011
A pan-HPV vaccine based on bacteriophage PP7 VLPs displaying broadly cross-neutralizing epitopes from the HPV minor capsid protein, L2Ebenezer Tumban, Julianne Peabody, David S Peabody, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
RNA Phage VLP-Based Vaccine PlatformsDavid S Peabody, Julianne Peabody, Steven B Bradfute, et al.
Biorxiv : the Preprint Server for Biology|April 22, 2024
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathyJonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
Research Square|July 1, 2024
Virus-like particle (VLP)-based vaccine targeting tau phosphorylated at Ser396/Ser404 (PHF1) site outperforms phosphorylated S199/S202 (AT8) site in reducing tau pathology and restoring cognitive deficits in the rTg4510 mouse model of tauopathyJonathan Hulse, Nicole Maphis, Julianne Peabody, et al.
Plos One|October 31, 2015
Epitope-Specific Anti-hCG Vaccines on a Virus Like Particle PlatformJerri Caldeira, Jeremiah Bustos, Julianne Peabody, et al.
Journal of Molecular Biology|April 20, 2011
Peptide epitope identification by affinity selection on bacteriophage MS2 virus-like particlesBryce Chackerian, Jerri do Carmo Caldeira, Julianne Peabody, et al.
Plos One|November 28, 2012
VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirusEbenezer Tumban, Julianne Peabody, Mitchell Tyler, et al.
Biorxiv : the Preprint Server for Biology|April 17, 2026
A VLP-based immunogen that elicits selective anti-Myostatin antibodies, enhances muscle mass and strength, and reduces adiposityQuiteria Jacquez, Julianne Peabody, Eduardo Hernandez Acosta, et al.
Pageof 3